00:36 , Oct 19, 2018 |  BC Innovations  |  Tools & Techniques

Allogeneic CARs on the horizon

With the first generation of autologous, personalized CAR T cell therapies on the market, the field is turning to allogeneic technologies to provide better scale and lower costs. But drug makers are learning that as...
18:17 , Oct 12, 2018 |  BC Week In Review  |  Clinical News

Clinical holds for Affimed's T cell bispecific following patient death

Affimed N.V. (NASDAQ:AFMD) fell $1.13 (24%) to $3.50 Oct. 9 after it placed a clinical hold on two studies of blood cancer candidate AFM11 following three treatment-related serious adverse events, including a patient death. The...
18:04 , Oct 12, 2018 |  BC Week In Review  |  Financial News

First-day pop for Allogene after year's largest biotech IPO on NASDAQ

Less than a year after it was founded, cell therapy company Allogene Therapeutics Inc. (NASDAQ:ALLO) raised $324 million late Oct. 10 in the largest IPO by a biotech on NASDAQ thus far in 2018. The...
17:56 , Oct 12, 2018 |  BC Week In Review  |  Company News

NHS, Gilead reach agreement for Yescarta

NHS England said it will cover Yescarta axicabtagene ciloleucel from Gilead Sciences Inc. (NASDAQ:GILD) through the Cancer Drugs Fund (CDF), making Yescarta the first CAR T available to adults in England. Last month, NHS England struck...
02:40 , Oct 11, 2018 |  BC Extra  |  Financial News

First-day pop for Allogene after year's largest biotech IPO on NASDAQ

Less than a year after it was founded, cell therapy company Allogene Therapeutics Inc. (NASDAQ:ALLO) raised $324 million late Wednesday in the largest IPO by a biotech on NASDAQ thus far in 2018. The company...
20:30 , Oct 9, 2018 |  BC Extra  |  Clinical News

Affimed sinks after placing clinical hold on bispecific T cell engager

Affimed N.V. (NASDAQ:AFMD) fell $1.13 (24%) to $3.50 Tuesday after it placed a clinical hold on two studies of blood cancer candidate AFM11 following three treatment-related serious adverse events, including a patient death. The product...
23:13 , Oct 5, 2018 |  BC Extra  |  Company News

NHS, Gilead reach agreement for Yescarta

NHS England said it will cover Yescarta axicabtagene ciloleucel from Gilead Sciences Inc. (NASDAQ:GILD) through the Cancer Drugs Fund (CDF), making Yescarta the first CAR T available to adults in England. Last month, NHS England...
20:23 , Oct 5, 2018 |  BC Week In Review  |  Financial News

Allogene IPO could be year's largest biotech listing on NASDAQ

In newly proposed terms for its planned IPO on NASDAQ, cell therapy start-up Allogene Therapeutics Inc. (South San Francisco, Calif.) hopes to sell 16 million shares at $16-$18. At the midpoint, Allogene would raise $272...
22:58 , Oct 2, 2018 |  BC Extra  |  Financial News

Allogene IPO could be year's largest biotech listing on NASDAQ

In newly proposed terms for its planned IPO on NASDAQ, cell therapy start-up Allogene Therapeutics Inc. (South San Francisco, Calif.) hopes to sell 16 million shares at $16-$18. At the midpoint, Allogene would raise $272...
20:22 , Oct 2, 2018 |  BC Extra  |  Preclinical News

Carl June, NIBR teams document CAR T resistance

A pair of Nature Medicine studies from CAR T pioneer Carl June and Novartis Institutes for BioMedical Research (NIBR) documented mechanisms that resulted in resistance to Kymriah tisagenlecleucel from Novartis AG (NYSE:NVS; SIX:NOVN) or its...